Clinical use and efficacy of biphasic insulin lispro 50/50 in people with insulin treated diabetes-A nationwide evaluation of clinical practice by Mungreiphy, N.K. et al.
This is an author produced version of Clinical use and efficacy of biphasic insulin lispro 
50/50 in people with insulin treated diabetes-A nationwide evaluation of clinical practice.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/85553/
Article:
Mungreiphy, N.K., Mamza, J., Lakhdar, A.F. et al. (3 more authors) (2015) Clinical use and 
efficacy of biphasic insulin lispro 50/50 in people with insulin treated diabetes-A nationwide
evaluation of clinical practice. Current Medical Research and Opinion, 31 (3). 493 - 501. 
ISSN 0300-7995 
https://doi.org/10.1185/03007995.2015.1008689
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
  
 
 
 
© 2014 Informa UK Ltd. This provisional PDF corresponds to the article as it appeared upon 
acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon. 
',6&/$,0(5 7KH LGHDV DQG RSLQLRQV H[SUHVVHG LQ WKH MRXUQDO¶V Just Accepted articles do not necessarily reflect those of Informa Healthcare (the Publisher), the Editors or 
the journal. The Publisher does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of the material contained 
in these articles. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be 
administered to verify the dosages, the method and duration of administration, and contraindications. It is the responsibility of the treating physician or other health care 
professional, relying on his or her independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Just Accepted 
articles have undergone full scientific review but none of the additional editorial preparation, such as copyediting, typesetting, and proofreading, as have articles published 
in the traditional manner. There may, therefore, be errors in Just Accepted articles that will be corrected in the final print and final online version of the article. Any use of the 
Just Accepted articles is subject to the express understanding that the papers have not yet gone through the full quality control process prior to publication. 
Just Accepted by Current Medical Research & Opinion 
Orignial Article 
Clinical use and efficacy of the biphasic insulin Humalog Mix50 in 
people with insulin treated diabetes ± a nationwide evaluation of 
clinical practice 
N.K. Mungreiphy, J. Mamza, A.F. Lakhdar, M. Bannister, J. Elliott, I. Idris 
doi: 10.1185/03007995.2015.1008689 
Abstract 
Objectives: This study aims to investigate the metabolic effects of Humalog 
0L[LQURXWLQHFOLQLFDOSUDFWLFHSDWLHQWV\HDUVROGZLWKGLDEHWHV
newly treated Humalog Mix50, were sourced from 6 secondary care 
services in the England. 
Methods: Detailed clinical parameters were compared at baseline, 3 and 6 
months post initiation. Responders was defined as HbA1c <7.5% 
(58mmol/mol) and/or HbA1c reduction of >1% (11mmol/mol) at 6 months. 
Results: HbA1c showed significant reduction: -0.93%(-10mmol/mol) and -
1.2% (-13mmol/mol) at 3 and 6 months respectively, while no significant 
change was noted for all the other parameters. When analysed according to frequencies of injections/day, 
greatest reduction was observed with the three-times a day regimen -1.0% (-11.0mmol/mol) and -1.3% (-
14.6mmol/mol) at 3 and 6 months respectively]. HbA1c reduction was greatest in the group who previously 
received a basal-bolus insulin regimen: [-0.8% (-9.0mmol/mol) and -1.5% (-16.2mmol/mol) at 3 and 6 months 
respectively]. Reduction in weight was observed at 3 months (-1.8kg 4.3) only for those who were previously 
on a basal-bolus insulin regimen. Insulin doses increased following conversion to Humalog Mix50, irrespective 
of the types of insulin used prior Humalog Mix50, but not associated with weight gain. The independent 
predictors of response to Humalog Mix50, were baseline HbA1c, Caucasian, presence of nephropathy, prior 
use of basal-bolus insulin and prior use of other premixed combination. 
Conclusion: Humalog Mix50 is therefore an effective therapeutic option for achieving glycaemic control in 
patients with suboptimal HbA1c levels, especially among those who were previously on basal-bolus insulin 
regimen and those who received it three times daily, with a neutral effect on weight parameters. 
Limitations: This was a retrospective study of routine clinical practice and is therefore limited by allocation bias 
andsome missing data.Information on rates of hypoglycaemia and quality of life are not available. 
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Abstract 
Objectives: This study aims to investigate the metabolic effects of Humalog Mix50 in routine 
FOLQLFDOSUDFWLFHSDWLHQWV\HDUVROGZLWKGLDEHWHVQHZO\WUHDWHG+XPDORJ0L[ZHUH
sourced from 6 secondary care services in the England.  
Methods: Detailed clinical parameters were compared at baseline, 3 and 6 months post initiation. 
Responders was defined as HbA1c <7.5% (58mmol/mol) and/or HbA1c reduction of >1% 
(11mmol/mol) at 6 months.  
Results: HbA1c showed significant reduction: -0.93%(-10mmol/mol) and -1.2% (-13mmol/mol) 
at 3 and 6 months respectively, while no significant change was noted for all the other 
parameters. When analysed according to frequencies of injections/day, greatest reduction was 
observed with the three-times a day regimen -1.0% (-11.0mmol/mol) and -1.3% (-
14.6mmol/mol) at 3 and 6 months respectively]. HbA1c reduction was greatest in the group who 
previously received a basal-bolus insulin regimen: [-0.8% (-9.0mmol/mol) and -1.5% (-
16.2mmol/mol) at 3 and 6 months respectively]. Reduction in weight was observed at 3 months 
(-1.8kg 4.3) only for those who were previously on a basal-bolus insulin regimen. Insulin doses 
increased following conversion to Humalog Mix50, irrespective of the types of insulin used prior 
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Humalog Mix50, but not associated with weight gain. The independent predictors of response to 
Humalog Mix50, were baseline HbA1c, Caucasian, presence of nephropathy, prior use of basal-
bolus insulin and prior use of other premixed combination.  
Conclusion: Humalog Mix50 is therefore an effective therapeutic option for achieving glycaemic 
control in patients with suboptimal HbA1c levels, especially among those who were previously 
on basal-bolus insulin regimen and those who received it three times daily, with a neutral effect 
on weight parameters.  
Limitations: This was a retrospective study of routine clinical practice and is therefore limited by 
allocation bias andsome missing data.Information on rates of hypoglycaemia and quality of life 
are not available. 
 
 
Introduction 
There is currently no consensus about the most appropriate insulin regimen to be chosen in 
people with diabetes [1]. NICE guidelines however recommend initiating insulin therapy with 
human neutral protamine Hagedorn (NPH) insulin or a long-acting analogue (basal insulin) 
injected at bed-time or twice daily according tRWKHSDWLHQW¶VQHHG[2] Thereafter, therapy can be 
intensified with prandial insulin (which may include a premixed therapy or basal-bolus regimen). 
While such basal-EROXVLQVXOLQLVZLGHO\UHJDUGHGDVWKHµJROGVWDQGDUG¶LQVXOLQUHJLPHQLQ
people with diabetes, the technicalities of this regimen coupled with the need for frequent insulin 
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dose adjustment resulted in our observation that in routine practice, glycaemic control remains 
suboptimal in many patients receiving a basal bolus insulin regimen. [3]  
 
In people without diabetes, basal insulin secretion represents approximately 50% of insulin 
secretion, with the remaining 50% being meal related insulin secretion [4]. Among patients with 
type 2 diabetes requiring intensive insulin therapy regimens in the form of multiple daily 
injection or insulin pump therapy, both regimen required 50% basal and 50% rapid acting insulin 
following dose titration [5]. Based on these, biphasic insulin lispro 50/50 (Humalog Mix50)  
containing 50% rapid-acting and basal insulin respectively, was developed to provide the 
physiological advantages of rapid and basal insulin in the convenience of a premixed formulation 
[6],QGHHGLQWHQVLILFDWLRQRILQVXOLQWKHUDS\ZKHUHSDWLHQWV¶EORRGJOXFRVHOHYHOVUHPDLQ
suboptimal after receiving biphasic insulin aspart 30/70, biphasic human insulin 30/70 or 
biphasic insulin lispro 25/75) has been shown to be achieved by switching to premixed regimens 
with greater prandial coverage (Humalog Mix50) [7,8,9].  There is however, limited post-market 
surveillance and/or real world evidence assessing how Humalog Mix50 is used in routine 
practice, as well as the effectiveness of this insulin regimen in patients with diabetes. This study 
specifically aims to investigate how this insulin is used in routine practice in the UK (e.g. first 
line, second line, third line insulin twice daily, thrice daily or in combination with prandial or 
basal insulin) as well as the effectiveness of Humalog Mix50 regimen in patients with diabetes.  
 
Methods 
Patient Selection and Analyses 
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Anonymised retrospective information on 229 patients using Humalog Mix50 in clinical practice 
was received from 6 centres across England. Demographic data of the patients which includes 
ethnicity, gender, type of diabetes, year of diabetes diagnosis, hypoglycaemia unawareness, 
height, weight and medications were included in the audit. At baseline, patients were divided 
according to the type of diabetes for analyses. Information on complications like stroke, 
peripheral artery disease, retinopathy, nephropathy and neuropathy were also assessed. Data  
were collated at the third and sixth month post commencement of Humalog Mix50.  All patients 
who had received Humalog Mix50 with available data for at least 6 months were eligible for 
inclusion. 
 
Data on the current antidiabetic and insulin therapy with details of dosing frequency and year of 
start were noted. Information on antidiabetic therapy including insulin prior to Humalog Mix50 
therapy and after starting Humalog Mix50 therapy at 3 and 6 months were evaluated. 
CompariVRQRIWKHFKDQJHVLQWKHSDWLHQWV¶+E$FHHLJKW%0,H*)5WRWDOFKROHVWHURO
triglyceride, HDL, LDL, systolic and diastolic BP prior to starting Humalog Mix50 therapy and 
Humalog Mix50 at  3 and 6 months post Humalog Mix50 initiation were calculated. 
 
 
Statistical Analysis 
Descriptive statistics are provided for patients according to their type of diabetes. Changes in 
HbA1c, weight, BMI, eGFR, total cholesterol, triglyceride, HDL, LDL, systolic and diastolic BP 
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from prior to starting Humalog Mix50 therapy and after starting Humalog Mix50 therapy at 3 
and 6 months were evaluated using paired t-test. Analysis of variance (ANOVA) was used to 
check the variation in Mean (±SD) of different variables. p-values of <0.05 were considered to 
be statistically significant in the analyses.  
  
ANOVA was applied to assess the effect of different dosing frequency of Humalog Mix50 
WKHUDS\SHUGD\RQWKHSDWLHQWV¶+E$FZHLJKW%0,H*)5WRWDOFKROHVWHUROWULJO\FHULGH
HDL, LDL, systolic and diastolic BP at the third and sixth months. Changes after starting 
+XPDORJ0L[WKHUDS\DWDQGPRQWKVZHUHDOVRHYDOXDWHGDFFRUGLQJWRWKHSDWLHQWV¶SULRU
medication using ANOVA. Statistical analyses were performed using StataSE 11 
 
Results 
There were two hundred and twenty-nine patients with detailed baseline information. 
Demographic information of patients is shown in table 1. Most of the patients were Caucasian. 
Thirty two patients have type 1 diabetes while one hundred and ninety seven patients have type 2 
diabetes, with mean type 2 diabetes duration of 18.35 (±7.9) years. Negligible amount of patients 
experienced hypoglycaemia unawareness . Mean HbA1c at baseline was 85mmol/mol (9.9%) 
and mean BMI was 34.8kg/m2 (Table 1). Micro- and macro vascular complications were 
significantly more prevalent in patients with type 2 diabetes. The majority of patients (51.7%) 
received a premixed insulin therapy as their first insulin regimen. Prior to Humalog Mix50 
therapy, most patients were on premixed insulin 30/70 (46.3%) and/or Metformin (47.2%) while 
few received Basal Bolus insulin (6.1%), Basal Acting (11.97%) or other oral therapy (14.4%) 
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such as Gliptins, Glucagon like peptide-1 analogues, sulphonylureas and thiazolidinediones.    
Most patients (40.4%) took Humalog Mix50 as their current insulin therapy three times daily 
with mean doses of 135.1 ± 75.3 units per day (1.4 ± 0.7 U/kg), followed by those (24.1% each) 
who took four times daily with mean doses of 90.6 ±62.7 units per day (0.93 ± 0.7 U/kg) and 
twice daily with mean doses of 90.6 ± 62.7 units per day (0.78 ± 0.4 U/kg). There were only 
11.4% patients who had Humalog Mix50 once a day with mean dose of 46.1 ± 68.7 units per day 
(0.49 ±0.3 U/kg).      
 
Table 2 shows the mean values of weight, BMI, HbA1c, GFR, total cholesterol, triglyceride, 
HDL, LDL, systolic and diastolic BP, prior to starting Humalog Mix50 therapy and at 3 and 6 
months after starting Humalog Mix50. HbA1c showed significant reduction at both time points 
of investigation while no significant change was noted for all the other parameters following the 
initiation of Humalog Mix50 (Table 2). However, when changes in parameters at 3 and at 6 
months were analysed according to frequencies of Humalog Mix50 injections per day, we 
observed significant differences for most parameters depending on the frequencies of Humalog 
Mix50 therapy being used (Table 3). HbA1c reduction was seen for all frequencies of Humalog 
Mix50 injection therapy (Figure 1), with the greatest reduction observed with the three times a 
day regimen.  Patients who took Humalog Mix50 four times a day showed reduction of weight 
and BMI at both 3 and 6 months, whereas patients with three and two times injections/day 
showed increment in the values. Total cholesterol and triglyceride levels were unchanged 
following initiation of Humalog Mix50.  
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The changes in weight, BMI, HbA1c, GFR, total cholesterol, triglyceride, HDL, LDL, systolic 
and diastolic BP after starting Humalog Mix50 therapy according to prior medication is reported 
in table 4. Among patients who were on basal bolus prior to Humalog Mix50 therapy, reduction 
in weight was observed at 3 months whereas the values increased at 3 and 6 months among those 
who were previously taking premix and basal insulin medication. HbA1c outcomes following 
Humalog Mix50 were significantly different depending on the insulin regimen used prior to 
Humalog Mix50. At 6 months, HbA1c reduction appears to be greatest in the group who 
previously received a basal bolus insulin regimen (Figure 2). Of note, in a separate subanalysis, 
similar outcome was observed among patients with type 2 diabetes as that from the whole cohort 
(result not presented here). Insulin doses increased following conversion to Humalog Mix50, 
irrespective of the types of insulin used prior to conversion to Humalog Mix50 (Table 5). The 
patient group who received the greatest amount of insulin were those who previously received a 
basal bolus insulin group prior to conversion to Humalog Mix50, (increase in insulin dose from 
0.78u/kg to 1.2u/kg. Reassuringly, this was not associated with weight gain (Table 4). 
 
Table 6 displays the logistic regression showing predictors of responders (n=170) versus non-
responders (n=59) to Humalog Mix50 therapy. Responder was defined as HbA1c reduction by 
1% or more at 3 months or 6 months or achieving HbA1c <7.5%% (58mmol/mol) at 6 months if 
baseline HbA1c >=7.5%(58mmol/mol). The response rate was 74%. The independent predictors 
of response to Humalog Mix50, after adjusting for other confounders were baseline HbA1c, 
Caucasian, presence of nephropathy and prior use of basal bolus insulin as well as prior use of 
other premixed combination (other than Humalog Mix50).  
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Discussion  
This audit of Humalog Mix50 provides useful insights into the current strategies in Humalog 
Mix50 prescribing as well as clinical effectiveness of this insulin in routine specialist clinical 
care  in England. The audit also allowed some analyses of the predictors of good glycaemic 
responses to Humalog Mix50, comparisons between different frequencies of Humalog Mix50 
being prescribed, as well as analyses of effectiveness and weight outcome, based on previous 
insulin regimen used prior to  Humalog Mix50.  
As a whole, this audit suggests that biphasic insulin regimen mix30 appears to be the most 
widely used first line insulin regimen in clinical practice.  When prescribed, Humalog Mix50 is 
often prescribed as a third or 4th line insulin regimen and is associated with a reduction in HbA1c 
at 3 and at 6 months.  The rate of responders to Humalog Mix50 - based on our strict definition 
of responders, (reduction in HbA1c by >1% or achieving HbA1c target of <7.5%(58mmol/mol), 
observed in this study was very high (74%), compared with only 35% of patients who responded 
to this insulin regimen seen in our previous study [10].  This may reflect the fact that the data 
from this audit was derived from data from specialist centres, whereas our previous data was 
derived from a UK general practice dataset.  
The majority of Humalog Mix50 is prescribed three times a day, which was also associated with 
the highest insulin dose/kg of insulin, compared with other frequencies of Humalog Mix50 
injection. This frequency of insulin injection is associated with weight gain. Although insulin 
intensification is widely recognised to be associated with weight gain [11,12], previous data has 
shown favourable effects of Humalog Mix50 regimen on weight [10,13]. No difference in 
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HbA1c reduction was observed across different frequencies of Humalog Mix50 injections, 
although greatest HbA1c reduction was observed among those who were prescribed three times 
day.  In line with this, previous studies have shown benefits of Humalog Mix50 compared to 
human insulin 70/30 or Humalog 75/25 [9,13] in reducing post-prandial glucose excursion [6].  
These benefits were augmented when Humalog Mix50 is given thrice daily compared with 70/30 
twice daily [9] or 70/30 thrice daily [14], but equivalent when compared with a basal bolus 
insulin regimen [15].  
When analysed according to the previous insulin regimen being used, those who converted to 
Humalog Mix50 from a previous basal bolus insulin regimen appears to show the greatest 
reduction in HbA1c, compared with those who was previously on a biphasic 30 or a long acting 
only insulin. The reason for this is unclear, and is out of the scope of this audit.  It is tempting to 
speculate that the complexities of a basal bolus insulin regimen when prescribed in obese 
patients with diabetes (such as in this patient cohort), is associated with reduced treatment 
compliance and hence treatment failure. To this end, converting these patients to a more fixed 
biphasic insulin regimen, with an appropriate prandial insulin cover might be beneficial.  Indeed, 
previous use of basal bolus insulin (along with the recognised, baseline HbA1c) is an 
independent predictor of success to Humalog Mix50 regimen. Presence of diabetic nephropathy, 
perhaps by virtue of declining GFR and increased risks of hypoglycaemia is also a predictor of 
response to Humalog Mix50.  Of note however, the patient group who received the greatest 
amount of insulin were those who previously received a basal bolus insulin group prior to 
conversion to Humalog Mix50, (increase in insulin dose from 0.78u/kg to 1.2u/kg), but this was 
not associated with weight gain. The explanation in the discordance between weight loss (at 
3months) and increased insulin dose unfortunately is outside the remit of this study, but we 
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would speculate that changes in lifestyle, compliance to treatment and eating habits from 
converting from a 4 injections a day to a fixed three injections per day may somewhat play a role 
in this.   
The magnitude of HbA1c reduction in this cohort was similar to that previously observed in the 
national exenatide audit in patients not on insulin [17].  However, in the same audit, HbA1c 
reduction was much less at three months among those who were on insulin and continued on 
insulin therapy (-0.51%) or among patients who discontinued insulin therapy following initiation 
of exenatide [17]. Patients in the previous exenatide audit however consisted entirely of patients 
with type 2 diabetes and were therefore slightly heavier (BMI 40.3, 40.2 and 39.4 respectively 
for different groups) than patients in this present audit (mean BMI 34.8kg/m2). 
This analysis had several limitations. Firstly, there was incomplete HbA1c and weight data due 
to problems of an audit in real-life clinical practice (e.g. missed follow-up, missed measurements 
or incomplete data entry). This has the potential of introducing bias among available results. 
Secondly, variability in clinical practice would influence insulin intensification strategy between 
centres. It important to note however that all data were collected from specialist centres with 
patients receiving input by specialist clinicians.  We were also unable to determine treatment 
compliance and variations in structured education programmes that patients may or may have not 
received. We also did not distinguish between type 1 and type 2 diabetes in our analysis because 
the small number of patients with type 1 diabetes in this data would limit any meaningful 
conclusion to patients with type 1 diabetes. However, where appropriate, we performed 
subanalysis in patients with type 2 diabetes alone, and the result was similar to the whole cohort. 
In addition, other than metabolic outcome, the aim of this study is look at prescribing pattern of 
Humalog Mix50 among all insulin treated patients with diabetes. Finally, data on quality of life 
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and hypoglycaemia is not available in this study. This is crucial, since any possible improvement 
in HbA1c, maybe driven by reduction in the frequency of insulin treatment, hypoglycaemia risks 
or lack of need to adjust insulin doses according to carbohydrate load.    
Conclusion 
Conversion to Humalog Mix50 regimen appears to be a reasonable therapeutic option among 
patients who are already on insulin therapy, with suboptimal glucose control.  Although the 
glycaemic response of this insulin regimen is heterogeneous; patients who were previously on a 
basal bolus insulin regimen and those who received three times a day Humalog Mix50 appeared 
to benefit most with a neutral effect on weight parameters.   
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Table 1: Demographic and baseline characteristics of the patients  
Variables (%) Total (n=229) / 
Mean (SD) 
Type 1 Diabetes 
(n=32) 
Type 2 Diabetes 
(n=197) 
p-Value 
Ethnicity     
Caucasian 166 (72.4) 29 (17.5) 137 (82.5)  
Non-Caucasian 63 (27.6) 3 (4.76) 60 (95.2) 0.013 
Gender     
Males 117 (51.1) 19 (16.24) 98 (83.8)  
Females 112 (48.9) 13 (11.6) 99 (88.4) 0.312 
Hypoglycaemia 
unawareness 
    
Yes 25 (11.7) 10 (40) 15 (60)  
No 188 (88.3) 20 (10.6) 168 (89.3) <0.001 
Complications     
Stroke 20 (8.7) 0 20 (100) 0.034 
Peripheral Artery 35 (15.3) 0 35 (100) 0.004 
Retinopathy 138 (60.3) 17 (12.3) 121 (87.7) 0.029 
Nephropathy 102 (44.5) 7 (6.9) 95 (93.1) <0.001 
Neuropathy 104 (45.4) 5 (4.8) 99 (95.2) <0.001 
First insulin regimen     
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Variables (%) Total (n=229) / 
Mean (SD) 
Type 1 Diabetes 
(n=32) 
Type 2 Diabetes 
(n=197) 
p-Value 
HumalogMix50 27 (18.1) 2 (7.4) 25 (92.6)  
Basal Insulin 36 (24.2) 6 (16.7) 30 (83.3)  
Premixed 80 (53.7) 10 (12.5) 70 (87.5)  
Short acting 6 (4.0) 1 (16.7) 5 (83.3) 0.735 
     
     
Mean Age (years) 63.18 (12.6) 52.84   (18.2) 64.86  (10.5) <0.001 
Diabetes duration (years) 19.12 (9.4) 24.1   (15.2) 18.35   (7.9) <0.001 
Duration of insulin regimen  
(years) 
11.41 (9.2) 21.71 (15.9) 9.64 (6) <0.001 
Height (m) 1.66 (0.1) 1.68   (0.1) 1.66 (0.1) 0.805 
Weight (kg) 96.76  (23.9) 81.02   (17.6) 99.15 (23.9) 0.049 
BMI (kg/m2) 34.8 (7.8) 28.48 (5.8) 35.81 (7.6) 0.086 
HbA1c (%) 9.9 (2.1) 9.64   (2.2) 9.95 (2.0) 0.568 
HbA1c (mmols/mol) 85 (23) 82 (24) 85 (21.9) 0.568 
eGFR (mls/min/m2) 69.76 (63) 78.46   (23.4) 68.35 (67.2) <0.001 
Total cholesterol (mmol/L) 4.31 (1.1) 4.51   (1.1) 4.28  (1.1) 0.922 
Triglyceride (mmol/L) 2.50 (1.6) 1.76   (1.8) 2.63 (1.5) 0.217 
HDL (mmol/L) 1.19 (0.4) 1.57  (0.46) 1.12 (0.4) 0.091 
LDL (mmol/L) 2.05 (0.8) 2.12  (0.8) 2.03 ( 0.9) 0.617 
Systolic BP (mmHg) 138.24 (18.8) 128.07 (11.7) 139.84 (19.2) 0.002 
Diastolic BP (mmHg) 73.88 (11.1) 72.47 (8.03) 74.10 (11.5) 0.02 
Values are quoted as count/actual numbers (%) or as mean (± sd.)         
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Table 2: Mean of the variables prior to starting Humalog Mix50 therapy and at 3rd and 6th months after 
starting Humalog Mix50 along with the differences of the means and level of significance   
    
 
Variables  Prior to starting 
Humalog Mix 50 
therapy 
3 months after 
starting Humalog 
Mix50 
Differences in 3 
months 
6 months after 
starting Humalog 
Mix50 therapy 
Differences in 6 months 
 
n Mean (sd) n Mean (sd) Mean change 
(3rd month-
prior) 
p-value n Mean (sd) Mean 
change (6th 
month-
prior) 
p-value 
Weight (kg) 220 96.8 (23.9) 139   94.8 (23.8) 
 
-1.04 (4.6) 
 
0.451 194 97.9  (25.9) 1.0 (9.6) 0.657 
BMI (kg/m2) 213 34.8 (7.8) 135 34.6  (8.7) 
 
-0.42  (1.8) 
 
0.850 187 35.4 (8.8) 
 
0.41 (3.4) 
 
0.441 
HbA1c (%) 227 9.9 (2.1)  159 9.2 (1.7) -0.93 (1.6) 
 
0.001 210 8.7 (1.7) 
 
-1.18 (1.9) 
 
P<0.001 
HbA1c 
(mmols/mol) 
227 85 (23.0) 159 77 (18.6) -10.2 (17.5) 0.001 210 73 (18.6) -12.9 
(20.8) 
P<0.001 
eGFR 
(mls/min/m2) 
214 69.8 (63) 133   66.3 (25.2) -.94 (11.2) 
 
0.544 181 67.7 (67.8) -2.28 
(89.1) 
 
0.750 
Total 
cholesterol 
(mmol/L) 
210 4.3 (1.1) 111 4.3 (1.3)  -0.01 (.8) 
 
0.715 168 4.3 (1.0) 
 
-0.05 (.9) 
 
0.858   
Triglyceride 188 2.5 (1.6) 100 2.6 (1.7) 
 
-0.13 (1.2) 
 
0.845 149 2.3 (1.5) 
 
-0.30 (1.2) 
 
0.265 
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(mmol/L) 
HDL (mmol/L) 169 1.2 (0.4) 85 1.2 (0.4) 
 
 0.01 (0.3) 
 
0.853 141 1.2 (.4) 
 
-0.02 (.3) 
 
0.820 
LDL (mmol/L) 127 2.1 (0.8) 66  2.1 (0.7) 
 
 -0.01 (.7) 
 
1.000 108 2.0 (.7) 
 
-0.06 (.8) 0.774 
Systolic BP 
(mm/Hg) 
221 138.2 (18.8) 132 135.1 (16.7) -0.29 (17.0) 
 
0.109 183 137.4 (17.9) -0.13 
(20.4) 
0.633 
Diastolic BP 
(mm/Hg) 
221 73.8 (11.1) 132 74.60 (9.9) 
 
0.65 (11.6) 0.540 183 73.1 (11.1) 
 
-1.04 
(11.5) 
0.488 
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Table 3: Changes after starting Humalog Mix50 therapy at 3rd and 6th months according to frequency per day 
 
Variables  Mix50 Freq per 
day 
Mean change in variables at 3 months (3 
months & prior) 
Mean change in variables at 6 months (6 
months & prior) 
Mean (SD) Freq p-value Mean (SD) Freq p-value 
Weight (kg) Four Times -.83 (2.5) 13  -1.92 (18.2)   37  
Three Times .91 (4.9)  72  2.26 (6.6)     84  
Two times 1.73 (3.5) 40  1.50 (4.1)     48  
Once 1.51 (7.2) 13  -.06 (4.8)     21  
Total 1.04 (4.6) 138 <0.001 1.00 (9.6)     190 <0.001 
BMI  (kg/m2) Four Times -.29 (.9)  13  -.66 (6.3)   36  
Three Times .38 (1.9)    72  .89 (2.5)   83  
Two times .69  (1.2)    37  .56 (1.5)   45  
Once .61 (2.9)    12  -.01 (1.8)   20  
Total .42 (1.8)    134 <0.001 .41 (3.4)   184 <0.001 
HbA1c (%) Four Times -.90 (1.6)   21  -.92 (2.4)   42  
Three Times -1.01 (1.5)   78  -1.34 (1.7)   90  
Two times -0.89 (1.8)   46  -1.13 (2.0)   51  
Once -0.52 (0.9)   11  -1.20 (2.0)   24  
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Total -0.92 (1.8) 156 0.089 -1.18 (1.9)   207 0.069 
GFR 
(mls/min/m2) 
Four Times -6.51 (21.2)   15  -3.23 (199.8)   35  
Three Times 1.17 (9.0)   66  -2.27 (16.5)   78  
Two times -1.63 (6.4)  38  -2.5 (9.4) 42  
Once -4.55 (15.3) 10  -.19 (17.8)   20  
Total -.99  (11.2)    129 <0.001 -2.28 (89.3)   175 <0.001 
Total choles-
terol 
(mmol/L) 
Four Times .11 (.5)   17  -.09 (1.0)  35  
Three Times -.04 (.9) 55  -.07 (.9)  71  
Two times -.05 (.8)   29  -.05 (.8)   35  
Once .20 (.3)  5  .13 (1.1)  19  
Total -.01 (.8  )   106 0.011 -.05 (.9)   160 0.344 
Trigly-ceride 
(mmol/L) 
Four Times -.54 (.8)   11  -.32 (1)   25  
Three Times -.07 (1.2)     50  -.30 (1.4)   62  
Two times .02  (1.3)    26  -.29 (1.1)   29  
Once -.42 (.6)   5  -.25 (1.1)   17  
Total -.12 (1.2)     92 0.157 -.30 (1.2) 133 0.092 
HDL 
(mmol/L) 
Four Times -.03 (.6)   16  -.09 (.5)   34  
Three Times .01 (.2)  35  -.03 (.2)     43  
Two times .04 (.2) 20  .03 (.2)     26  
Once 0 (.1) 4  .04 (.2)     18  
Total .01 (.3)  75 <0.001 -.02 (.3)     121 <0.001 
LDL 
(mmol/L) 
Four Times .28 (.5) 15  -.01 (.8)   31  
Three Times -.08 (.9)   26  -.21 (.7)     28  
Two times -.33 (.7)  13  -.13 (.8)     15  
Once .25 (.1) 4  .18 (1)      16  
Total -.02 (.8)  58 0.007 -.06 (.8)     90 0.440 
Systolic BP 
(mm/Hg) 
Four Times -3.94 (24.18)   16  -3.08 (22.69)   37  
Three Times -.33 (15.88)  69  .12 (20.27)     78  
Two times 4.77 (15.17) 35  3.37 (20.07)     43  
Once -3.91 (16.74)  11  -.85 (16.90)   20  
Total .29 (17.04 )  131 0.108 .129 (20.36)    178 0.558 
Diastolic BP 
(mm/Hg) 
Four Times 3.44 (16.05)   16  -4.11 (11.46)   37  
Three Times -.93 (10.19)     69  -.76 (10.40)     78  
Two times 1.91 (10.80)     35  .09 (13.56)     43  
Once 2.45 (14.83)     11  1.05 (10.11)   20  
Total .65 (11.60)     131 0.054 -1.04 (11.45)       178 0.211 
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Table 4: Changes after starting Humalog Mix50 therapy at 3rd and 6th months according to insulin 
medication prior to conversion to Mix50  
Changes in 
Variable  
Prior 
Medicatio
n 
Mean change at 3 months 
(3 months-prior) 
Mean change at 6 months 
(6 months-prior) 
Mean SD Freq p-value Mean SD Freq p-value 
Weight 
(kg) 
Premix 1.31 (4.1) 60  .09 (12) 83  
Basal Bolus -1.79 (4.3) 8  .09 (2.2) 10  
Basal Ins 1.46 (6) 19  1.15 (7.5) 26  
Total 1.06 (4.6) 87 0.110 .32 (10.6) 119  <0.001 
BMI 
(kg/m2) 
Premix 0.49 (1.5) 58  .04 (4.0) 80  
Basal Bolus -0.70 (1.7) 8  .01 (.8) 10  
Basal Ins 0.54 (2.2) 18  .40 (2.5) 25  
Total .39 (1.7) 84 0.261 .11 (3.5) 115 <0.001 
HbA1c (%) Premix -.64 (6.9) 69  -.85 (1.7) 93  
Basal Bolus -.82 (0.7) 9  -1.48 (1.3) 11  
Basal Ins -.43 (1.8) 24  -.87 (2.6) 30  
Total -.06 (5.7) 102 0.016 -.91 (1.9) 134 0.005 
GFR 
(mls/min/m
2) 
Premix -0.40 (12.9) 61  -11.41 (94.3) 80  
Basal Bolus -7.54 (16.4) 8  2.21 (9.5) 10  
Basal Ins -2.81 (7.9) 20  -3.07 (10.6) 25  
Total -1.59 (12.3) 89 0.028 -8.42 (78.8) 115 <0.001 
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Total 
cholesterol 
(mmol/L) 
Premix .18 (0.7) 46  -.01 (.8)  74  
Basal Bolus .37 (0.4) 3  -.16 (.6) 8  
Basal Ins .19 (0. 7) 20  .27 (.6) 23  
Total .19 (0.7) 69 0.632 .04 (.8) 105 0.088 
Triglycerid
e (mmol/L) 
Premix -.22 (1) 37  -.20 (1.3) 61  
Basal Bolus -1.17 (1.1) 3  -.64 (1.9) 7  
Basal Ins .55 (1.3) 17  .02 (.7) 19  
Total -.04 (1.2) 57 0.424 -.19 (1.2) 87 0.041 
HDL 
(mmol/L) 
Premix -.02 (.4) 31  -.06 (.4) 52  
Basal Bolus .033 (.1) 3  .04 (.1) 5  
Basal Ins .07 (0.2) 11  .05 (.1) 18  
Total .002 (0.4) 45 0.003 -.03 (.3) 75 <0.001 
LDL 
(mmol/L) 
Premix .13 (.4) 23  -.14 (.7) 36  
Basal Bolus .37 (.6) 3  -.12 (.7) 5  
Basal Ins .55 (.4) 4  .19 (.6) 10  
Total .21 (.4) 30 0.822 -.08 (.7) 51 0.827 
Systolic BP  
(mm/Hg) 
Premix .93 (16.4) 59  1.71 (18.6) 78  
Basal Bolus -12.13 18.6) 8  -9.1 (16) 10  
Basal Ins -3.29 (22.9) 17  .5 (21.3) 26  
Total -1.17 (18.3) 84 0.229 .48 (19.1) 114 0.541 
Diastolic 
BP 
(mm/Hg) 
Premix 2.68 (11.2) 59  .23 (9.8) 78  
Basal Bolus -6.5 (16.6) 8  -8.8 (13.1) 10  
Basal Ins -5.06 (13.3) 17  -1.23 (13.3) 26  
Total 0.24 (12.6) 84 0.273 -.89 (11.2) 114 0.107 
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Table 5: Total mean (sd) dose of insulin prior to Mix50 treatment = 84.7 (50.1) units/day or 0.88 (0.5) 
U/kg per day. OD= once daily, BD=twice daily, TDS=three times a day, QDS= four times a day 
 N(%) 
Prior Insulin 
dose 
(Units/Kg/Day) 
Mean (SD) 
N 
(%) 
Baseline Mix50 dose 
(Units/Kg/Day) 
Mean (SD) 
MD 
(Se) 
P 
value 
Total 141 0.88 (0.5) 215 1.03 (0.7) 0.15 
(0.07) 
0.01 
Prior Regimen       
Basal bolus 14 0.54 (0.3) 14 0.80 (0.4) 0.26 
(0.1) 
0.03 
Basal insulin 30 0.78 (0.5) 31 1.20 (1.0) 0.42 
(0.2) 
0.02 
Other 
premixed 
97 0.96 (0.5) 96 1.09 (0.6) 0.13 
(0.08) 
0.05 
       
Frequency of 
Mix50 
      
OD 24 0.41 (0.3) 24 0.49 (0.3) 0.08 
(0.09) 
0.2 
BD 95 0.98 (0.4) 51 0.77 (0.4) -0.21 
(0.07) 
0.9 
TDS 22 0.91 (0.5) 88 1.38 (0.7) 0.47 
(0.2) 
0.002 
QDS - - 52 0.93 (0.7)   
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Table 6:  
 
 
 
 
 Predictors  OR 95% CI p value 
HbA1c (%)* 1.45 [1.21,1.74] <0.001 
Ethnicity 
  
Non-caucasian 1.00 - 
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Caucasian 1.87 [0.99,3.53] 0.05 
Nephropathy 
  
No 1.00 
 
Yes 2.13 [1.06,4.27] 0.03 
Prior Insulin therapy   
Basal bolus 3.67 [1.02,13.14] 0.05 
Basal insulin 1.46 [0.72,2.96] 0.3 
Premixed (Non-HM50) 2.89 [1.86,4.48] 0.001 
Table: Logistic regression showing predictors of responders (n=170) versus non-responders (n=59) to 
Humalog Mix50 therapy 
*Responders: Predictor of response if HbA1c reduction by 1% or more at 3 months or 6 months or 
achieving HbA1c < 7% at 6 months if baseline HbA1c >=7.5% 
 
Figure 1:   
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